APTX News and Press, Aptinyx Inc. From 06/11/21

Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%,&...

Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...

The following slide deck was published by Aptinyx Inc. in conjunction with this event. For further details see: Aptinyx Investor Presentation - Slideshow

Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q1 2021 Earnings Call May 13, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q1 2021 Earnings Call Transcript

Aptinyx Inc. (APTX) Q1 2021 Earnings Conference Call May 13, 2021, 05:00 PM ET Company Participants Nick Smith - VP of Corporate Development & IR Norbert Riedel - CEO Ashish Khanna - CFO & CBO Andy Kidd - President & COO Kathryn King - SVP of Clinical Development Harald Murck - VP...

Aptinyx (APTX): Q1 GAAP EPS of -$0.22 misses by $0.01.Revenue of $1M (+23.5% Y/Y)Press Release For further details see: Aptinyx EPS misses by $0.01

Enrollment on track in both Phase 2b studies of NYX-2925 in chronic pain — data readouts expected 1H 2022 Preparing for NYX-783 Phase 2b PTSD study following recent FDA meeting — study initiation expected in 2H 2021 Recommenced Phase 2 study of NY...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company’s Board of Directors. Dr. Miller currently ser...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to...

Aptinyx (APTX) presents additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder ((PTSD)). The study, enrolling 153 patients, consisted of two four-week treatment stages comparing once-daily oral dosing of NYX-783—10mg or 50mg—...